Sunesis Pharmaceuticals (NASDAQ:SNSS) has been given a $3.00 price objective by analysts at Cantor Fitzgerald in a research note issued on Tuesday. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 11.11% from the company’s previous close.

A number of other analysts also recently weighed in on the stock. ValuEngine downgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Zacks Investment Research downgraded shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. Oppenheimer initiated coverage on shares of Sunesis Pharmaceuticals in a report on Tuesday, November 21st. They issued an “outperform” rating and a $7.00 target price on the stock. Cowen restated a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Thursday, November 2nd. Finally, UBS began coverage on shares of Sunesis Pharmaceuticals in a report on Monday, November 20th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $3.63.

Sunesis Pharmaceuticals (SNSS) traded down $0.14 during trading on Tuesday, hitting $2.70. 70,300 shares of the stock were exchanged, compared to its average volume of 120,266. Sunesis Pharmaceuticals has a 12-month low of $1.82 and a 12-month high of $4.45. The company has a debt-to-equity ratio of -0.34, a quick ratio of 1.84 and a current ratio of 1.84.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). During the same period in the previous year, the company posted ($0.62) EPS. equities analysts forecast that Sunesis Pharmaceuticals will post -1.58 earnings per share for the current fiscal year.

In other news, Director Dayton Misfeldt purchased 400,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The stock was purchased at an average cost of $2.00 per share, with a total value of $800,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Mpm Oncology Impact Management purchased 81,500 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The shares were purchased at an average cost of $2.77 per share, with a total value of $225,755.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 506,800 shares of company stock valued at $1,091,282. 10.21% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its position in Sunesis Pharmaceuticals by 1.1% in the 1st quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after buying an additional 1,230 shares during the period. Wells Fargo & Company MN boosted its position in Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 18,254 shares during the period. Vanguard Group Inc. boosted its position in Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after buying an additional 23,819 shares during the period. Sphera Funds Management LTD. boosted its position in Sunesis Pharmaceuticals by 54.6% in the 2nd quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 68,212 shares during the period. Finally, Virtu KCG Holdings LLC purchased a new stake in Sunesis Pharmaceuticals in the 2nd quarter valued at about $208,000. 38.43% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/12/05/sunesis-pharmaceuticals-snss-given-a-3-00-price-target-by-cantor-fitzgerald-analysts.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.